Search

Your search keyword '"Advani, Ranjana"' showing total 1,914 results

Search Constraints

Start Over You searched for: Author "Advani, Ranjana" Remove constraint Author: "Advani, Ranjana"
1,914 results on '"Advani, Ranjana"'

Search Results

1. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

2. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma

3. Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation

4. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

5. Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium

9. DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set

10. Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era

11. The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network

14. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

16. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

17. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV

18. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

19. Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience

21. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

22. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

24. Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma

25. Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria

27. Current Frontline Treatment of Diffuse Large B-Cell Lymphoma

29. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

30. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center

31. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma

33. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.

35. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

36. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma

37. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

38. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

39. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

40. A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single cell analysis

41. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023

42. Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era

44. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

45. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial

46. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

47. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

48. ABCL-455 Multicenter Retrospective Analysis of Single-Route Prophylaxis in Aggressive B-Cell Lymphomas

49. HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1

50. HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Catalog

Books, media, physical & digital resources